Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2022)

Top healthcare stocks in 2022 ranked by overall Zen Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Score, the 3 best healthcare stocks to buy right now are:

COLLPLANT BIOTECHNOLOGIES (NASDAQ:CLGN) is the top healthcare stock with a Zen Score of 79, which is 47 points higher than the healthcare sector average of 32. It passed 25 out of 33 due diligence checks and has strong fundamentals. COLLPLANT BIOTECHNOLOGIES has seen its stock lose -37.49% over the past year, underperforming other healthcare stocks by -10 percentage points.

COLLPLANT BIOTECHNOLOGIES has an average 1 year price target of $21.50, an upside of 143.76% from COLLPLANT BIOTECHNOLOGIES's current stock price of $8.82.

COLLPLANT BIOTECHNOLOGIES stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering COLLPLANT BIOTECHNOLOGIES, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

STAAR SURGICAL (NASDAQ:STAA) is the second best healthcare stock with a Zen Score of 76, which is 44 points higher than the healthcare sector average of 32. It passed 26 out of 33 due diligence checks and has strong fundamentals. STAAR SURGICAL has seen its stock lose -50.07% over the past year, underperforming other healthcare stocks by -23 percentage points.

STAAR SURGICAL has an average 1 year price target of $106.00, an upside of 86.95% from STAAR SURGICAL's current stock price of $56.70.

STAAR SURGICAL stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering STAAR SURGICAL, 50% have issued a Strong Buy rating, 25% have issued a Buy, 25% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

CATALYST PHARMACEUTICALS (NASDAQ:CPRX) is the third best healthcare stock with a Zen Score of 74, which is 42 points higher than the healthcare sector average of 32. It passed 24 out of 33 due diligence checks and has strong fundamentals. CATALYST PHARMACEUTICALS has seen its stock return 21.14% over the past year, overperforming other healthcare stocks by 48 percentage points.

CATALYST PHARMACEUTICALS has an average 1 year price target of $11.60, an upside of 70.09% from CATALYST PHARMACEUTICALS's current stock price of $6.82.

CATALYST PHARMACEUTICALS stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering CATALYST PHARMACEUTICALS, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 70 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

SIGA TECHNOLOGIES (NASDAQ:SIGA) has an annual dividend yield of 6.09%, which is 4 percentage points higher than the healthcare sector average of 1.86%.

SIGA TECHNOLOGIES's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

FRESENIUS MEDICAL CARE AG & KGAA (NYSE:FMS) has an annual dividend yield of 5.26%, which is 3 percentage points higher than the healthcare sector average of 1.86%. FRESENIUS MEDICAL CARE AG & KGAA's dividend payout is not stable, having dropped more than 10% four times in the last 10 years. FRESENIUS MEDICAL CARE AG & KGAA's dividend has not shown consistent growth over the last 10 years.

FRESENIUS MEDICAL CARE AG & KGAA's dividend payout ratio of 52.3% indicates that its high dividend yield is sustainable for the long-term.

GLAXOSMITHKLINE (NYSE:GSK) has an annual dividend yield of 5.05%, which is 3 percentage points higher than the healthcare sector average of 1.86%. GLAXOSMITHKLINE's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. GLAXOSMITHKLINE's dividend has shown consistent growth over the last 10 years.

GLAXOSMITHKLINE's dividend payout ratio of 86.4% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -3.29% in the last day, and up 4.26% over the last week. BAUDAX BIO was the among the top losers in the healthcare sector, dropping -31.53% yesterday.

Baudax Bio shares are trading lower after the company announced a $2 million registered direct offering.

Based on WallStreetZen's Valuation Score, the 3 most undervalued healthcare stocks right now are:

SESEN BIO (NASDAQ:SESN) is the most undervalued healthcare stock based on WallStreetZen's Valuation Score. SESEN BIO has a valuation score of 100, which is 66 points higher than the healthcare sector average of 34. It passed 7 out of 7 valuation due diligence checks.

SESEN BIO's stock has dropped -80.71% in the past year. It has underperformed other stocks in the healthcare sector by -54 percentage points.

UNIVERSE PHARMACEUTICALS (NASDAQ:UPC) is the second most undervalued healthcare stock based on WallStreetZen's Valuation Score. UNIVERSE PHARMACEUTICALS has a valuation score of 100, which is 66 points higher than the healthcare sector average of 34. It passed 7 out of 7 valuation due diligence checks.

UNIVERSE PHARMACEUTICALS's stock has dropped -64.89% in the past year. It has underperformed other stocks in the healthcare sector by -38 percentage points.

ADAPTHEALTH (NASDAQ:AHCO) is the third most undervalued healthcare stock based on WallStreetZen's Valuation Score. ADAPTHEALTH has a valuation score of 86, which is 52 points higher than the healthcare sector average of 34. It passed 6 out of 7 valuation due diligence checks.

ADAPTHEALTH's stock has dropped -27.85% in the past year. It has underperformed other stocks in the healthcare sector by -1 percentage points.